David is the VP of Research at Insmed Incorporated, where he is part of a team developing novel, targeted therapies to help serve the critical unmet needs of patients battling serious rare diseases. Prior to joining Insmed in 2018, David worked at Aradigm (1996 to 2018) covering all phases of product development and led the development of preclinical research, CMC activities and intellectual property. Prior to joining Aradigm, David worked at Genentech, Inc. (1988 to 1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis in 1993. David holds a chemical engineering degree from MIT (SB) and UC Davis (MS) and a pharmacy degree from the University of Sydney (PhD). David has served in many external roles with industry, academic and regulatory colleagues and is currently the President-Elect of the International Society for Aerosols in Medicine (ISAM). David has also chaired the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS).
